Every SEC Form 3/4/5 on record for this filer (CIK 1699737) — 7 issuers, 12 transactions. Section-16 filings only: what they filed, not a biography, and titles are as filed on their latest form at each issuer.
This filer is an entity, not a person. This reporting owner's name carries a corporate/fund legal form, so it is an ENTITY filing under Section 16 — typically a fund with a board-designation right or a 10% holder — not an individual. Its 'director' rows are the entity's designation right, not a person's board seat.
| Ticker | Company | Role as filed | On file | Forms | Open-market net |
|---|---|---|---|---|---|
| KLRS | Kalaris Therapeutics, Inc. | 10% owner | 2025-03-25 → 2026-05-22 | 3 | $1M |
| MLYS | Mineralys Therapeutics, Inc. | 10% owner | 2023-02-09 → 2025-03-17 | 7 | $16M |
| VTVT | vTv Therapeutics Inc. | 10% owner | 2024-02-29 → 2024-12-06 | 2 | — |
| NGNE | Neurogene Inc. | 10% owner | 2024-11-27 → 2024-11-27 | 2 | — |
| CRGX | CARGO Therapeutics, Inc. | 10% owner · lapsed | 2023-11-09 → 2024-06-03 | 3 | $5M |
| SRRK | Scholar Rock Holding Corp | 10% owner · lapsed | 2023-06-21 → 2023-10-18 | 2 | — |
| GRPH | Graphite Bio, Inc. | 10% owner · lapsed | 2021-06-24 → 2022-04-13 | 9 | $895,198 |
| Ticker | Date | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| KLRS | 2026-05-20 | Buy | 244,300 | $4.83 | $1M | 2,224,147 |
| MLYS | 2025-03-13 | Buy | 600,000 | $13.50 | $8M | 5,674,916 |
| CRGX | 2024-05-30 | Buy | 294,000 | $17.00 | $5M | 4,415,689 |
| MLYS | 2024-02-12 | Buy | 555,555 | $13.50 | $7M | 5,074,916 |
| GRPH | 2021-12-15 | Buy | 22,329 | $10.19 | $227,533 | 7,814,180 |
| GRPH | 2021-10-15 | Buy | 2,300 | $12.49 | $28,727 | 7,590,166 |
5 of 7 issuers are covered and open a security page; the rest are on file here only.
